Latest Stem Cell Therapeuti (SCTPF) Headlines Stem Cell

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Stem Cell Therapeuti (SCTPF) Headlines

Stem Cell Therapeutics Strengthens its Board of Directors
Marketwire - Mon Mar 10, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that Mr. Luke Beshar and Dr. Thomas Reynolds have been appointed to the Company's Board of Directors.

Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Marketwire - Thu Jan 30, 6:38AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, is pleased to announce that its Board of Directors has elected Dr. Calvin R. Stiller as Chairman of the Board. Dr. Stiller has been a member of the Board since July 2011 and served as Lead Director and Chair of the Governance and Nominating Committee.

Stem Cell Therapeutics Announces Resignation of Director
Marketwire - Mon Jan 27, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, announces that effective today, Mr. David Allan has resigned from its board of directors.

Stem Cell Therapeutics Provides Corporate Update
Marketwire - Mon Jan 13, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today provided the following six-month corporate update:

Stem Cell Therapeutics Appoints Dr. Robert Kirkman to Its Board of Directors
Marketwire - Tue Dec 17, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that industry veteran Dr. Robert L. Kirkman has been appointed to the Company's Board of Directors.

Stem Cell Therapeutics Completes $33 Million Private Placement
Marketwire - Fri Dec 13, 3:50PM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell- related therapeutics, is pleased to announce that it has raised gross proceeds of $33 million through a private placement of units. The financing proceeds will be used to advance the Company's CD47 cancer stem cell program through IND-enabling studies, manufacturing and phase 1 clinical trials.

Stem Cell Therapeutics Receives U.S. Orphan Drug Designation for the Use of Tigecycline to Treat Acute Myeloid Leukemia
Marketwire - Thu Oct 31, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that it has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) for the use of tigecycline in the treatment of acute myeloid leukemia (AML).

Stem Cell Therapeutics Strengthens CD47 Franchise With Acquistion of Complementary Antibody Program
Marketwire - Thu Oct 17, 6:01AM CDT
Stem Cell Ther apeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), a biopharmaceutical immuno-oncology company developing cancer stem cell-related therapeutics, today announced that it has entered into an option agreement to exclusively license worldwide rights to a panel of fully human monoclonal antibodies targeting the SIRPa protein (CD172a). The technology was developed by scientists at the University Health Network, the University of Toronto, through the Toronto Recombinant Antibody Centre (TRAC), and The Hospital for Sick Children (SickKids), in Toronto, Ontario.

Stem Cell Therapeutics Adopts Shareholder Rights Plan
Marketwire - Tue Sep 17, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), a biopharmaceutical company developing cancer stem cell-related therapeutics, today announces that it has adopted a shareholder rights plan (the "Plan") effective September 16, 2013. The Company will be seeking shareholder approval of the Plan at its next annual general and special meeting of shareholders.

Stem Cell Therapeutics Advances CD47 Antagonist Program Into IND-Enabling Phase
Marketwire - Mon Sep 09, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), a biopharmaceutical company developing cancer stem cell- related therapeutics, today announced that it has advanced its CD47 antagonist program into an Investigational New Drug (IND) enabling phase. In collaboration with a contract manufacturing organization, Stem Cell Therapeutics (SCT) will begin the manufacturing process to generate drug for formal toxicology studies and a subsequent phase I clinical study, which is anticipated to begin in H2/2015.

Trillium Therapeutics Inc. (TRIL) Stock Research Links

TRIL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cracking Down on Insider Trading: Legal vs Illegal

Updated Category News Views 9

Why the Insider Trading Line Isn't Always Clear-Cut Insider trading is one of those buzzwords that conjures up images of Wall Street shenanigans and pricey legal battles. But believe it or not, trading on insider info isn’t always a one-way ticket to a federal prison. What determines its legality often hinges on how the information was obtained and used. It's a...

Continue Reading
NUH Revolutionizes Eye Care with Multidisciplinary Clinics

Updated Category News Views 5

Looking Back at Four Decades of Eye Care Excellence Sitting in the middle of Singapore, the National University Hospital's Ophthalmology Department has chalked up a solid 40 years serving up top-notch eye care. This ain't just about celebrating another year; it's about shaking things up with fresh approaches to treating tricky eye disorders. They're not resting on any...

Continue Reading
Dott's Q3 2026: Micromobility Growth Soars High

Updated Category News Views 5

Riding the Wave of Profit in Micromobility Sometimes all you need is a quick jolt of genius to turn the wheels of fortune. Dott seems to have hit that sweet spot in Q3 of 2026. Deploying 45,000 new vehicles wasn’t just a logistical feat; it was a calculated bet that paid off handsomely, bolstering their business to soaring heights. Performance that Packs a Punch The Q3...

Continue Reading
Harbour BioMed's Batoclimab Injected Into Myasthenia Market

Updated Category News Views 7

China's Green Light for Batoclimab When a new drug approval hits, particularly in a crucial market like China, it's a big deal. Harbour BioMed's recent go-ahead from the National Medical Products Administration (NMPA) for their Batoclimab injection is no exception. This marks the first full clinical cycle completion of an anti-FcRn treatment for generalized myasthenia...

Continue Reading
GoldMining's 2025 Report: Zero Incidents, Big Green Goals

Updated Category News Views 4

GoldMining Inc. Shows a Clear Green Streak Sometimes, you're caught off guard by a company's clear dedication to getting things right, and GoldMining Inc.'s latest sustainability report shows they're not just chasing fool's gold. They've laid out a solid roadmap. With the rollers they've got—swapping environmental chaos for responsible exploration—these guys have...

Continue Reading
JJ Lin's Iconic Singapore Grand Prix Show With 20 Songs

Updated Category News Views 1

Nothing beats the thrill of a live performance under a night sky, with the adrenaline of a Formula 1 race still in the air. On October 9, 2026, Mandopop superstar JJ Lin captivated the crowd at the Padang Stage of the Singapore Grand Prix, delivering not just a concert but a spectacle of international scale. Stage Spectacle with Precision JJ Lin took control like a...

Continue Reading
Better Home & Finance Faces Class Action: What's Next?

Updated Category News Views 1

Stock Hit and Legal Drama Panic set in when Better Home & Finance Holding Company took a 28.5% nosedive after spilling some less-than-sweet news. Their promise of hitting a billion in monthly loans? Stuck in limbo as borrower trepidation reared its ugly head amidst rising rates. Investors felt the heat, watching shares skydive $12.17, landing them at a bruised $30.52. A...

Continue Reading
ANCEL's Super Starter Impresses with Performance Boost

Updated Category News Views 3

More Than a Quick Fix: ANCEL's Impact Ever been frustrated because your car just won't start? Happens to the best of us, especially when that cold snap hits or your vehicle's been lounging around too long. ANCEL's Super Starter devices—let's talk about 'em. They've been making a name for themselves in the starting game, and I'm not yanking your chain here. According to...

Continue Reading
Unicycive Faces Legal Heat Amid Stock Tumble

Updated Category News Views 0

Unicycive Therapeutics' Rough Ride In this wild market, sometimes even the most seasoned investors get blindsided. Unicycive Therapeutics (NASDAQ: UNC) shareholders are currently caught in a storm with their stock nose-diving by 39.1% on June 30, 2026. It's like being taken to the cleaners without the decency of a warning. Failed Expectations & FDA Blues Here's the...

Continue Reading
CardVault by Tom Brady Expands to Pittsburgh

Updated Category News Views 4

Tom Brady’s CardVault Hits Pittsburgh’s Historic Strip District Pittsburgh just got another feather in its cap with CardVault by Tom Brady marking its 20th store at The Terminal. As if this city needed more sports excitement! Pittsburgh, with its die-hard Steelers, Penguins, and Pirates fans, snags a premium spot for sports collectibles. A Prime Spot for Serious...

Continue Reading

Top 5 Most Recently Viewed Articles

NOVONIX Secures $754 Million Conditional Loan for New Facility

Updated Category News Views 224

NOVONIX Secures Conditional Commitment from the U.S. Department of Energy NOVONIX Limited, a prominent player in the battery materials and technology sector, has recently announced a significant step towards its future expansion. A conditional commitment for a loan of up to US$754.8 million has been made available through one of its wholly-owned subsidiaries based in the...

Continue Reading
The Growth of the Aircraft Mounts Market Towards USD 1.9 Billion

Updated Category News Views 155

Understanding the Aircraft Mounts Market The aircraft mounts market is making significant strides, currently valued at USD 886.5 million, and projected to soar to USD 1.9 billion by the year 2034. This impressive growth is primarily fueled by the expansion of the aviation industry and increasing demands for air travel. Key Drivers of Market Growth With the global middle...

Continue Reading
Nokia and Surge Team Up for Revolutionary Internet Access

Updated Category News Views 198

Nokia and Surge Unite for Enhanced Connectivity Nokia has embarked on an exciting journey with Surge, a prominent telecommunications provider, to improve internet accessibility across Indonesia. This collaboration marks a significant step toward delivering affordable high-speed internet services in regions that currently face connectivity challenges. The Shift to 5G Fixed...

Continue Reading
TrustCo Bank Corp NY's Financial Metrics Reflect Strength

Updated Category News Views 97

TrustCo Bank Corp NY’s Performance Analysis TrustCo Bank Corp NY (NASDAQ: TRST) has recently released a comprehensive overview of its financial performance for the first three quarters, comparing its key metrics against industry peers. This analysis covers several significant indicators such as the Efficiency Ratio, Common Equity Tier 1 Capital Ratio, Cost of Funds, and...

Continue Reading
European Residential REIT's 2024 Financial Performance Unpacked

Updated Category News Views 340

Overview of European Residential REIT's Annual Results European Residential Real Estate Investment Trust (ERES) has released its results for the fiscal year ending December 31, 2024. This detailed report outlines the strategic measures taken throughout the year to enhance operational and financial performance. Key Events and Strategic Initiatives In a significant move,...

Continue Reading